Cardiac Sarcoidosis: Cell-free DNA as Biomarkers
Innovative research on Cell-free DNA (cfDNA) and other novel biomarkers for improved cardiac sarcoidosis and heart health outcomes.
Highlights:
- Biomarkers such as ACE and troponins are crucial for diagnosing cardiac sarcoidosis and myocarditis
- New markers like microRNAs and cell-free DNA show promise for better diagnosis and treatment
- Diagnosis remains challenging due to overlapping symptoms and non-specific biomarkers
Sarcoidosis is a systemic inflammatory autoimmune disorder containing non-caseating granulomas (NCG). NCGs are composed of active immune cells that lack necrotic tissue (1✔).
When non-caseating granulomas affect the heart, it leads to serious complications like heart failure (HF), ventricular arrhythmias, and sudden death. This condition is known as cardiac sarcoidosis (CS).
‘Cell-free DNAs (#cfDNAs) are used as biomarkers for disease diagnostics, prognostics, and therapeutics of Cardiac Sarcoidosis. #heartdisease #sarcoidosis #medindia’
Improving Heart Disease Diagnosis with Biomarkers
Myocarditis is a disease condition causing inflammation in the heart muscles. It can progress into a chronic form known as inflammatory cardiomyopathy. Both CS and IC cause inflammation and damage to the heart. However, diagnosis of the disease is challenging.Endomyocardial biopsy (EMB), FDG-PET scans, and cardiac MRI are some of the diagnostic methods used but significant gaps remain in diagnosing and treating these heart conditions.
Diagnosis can be improved by identifying the biomarkers that cause the diseases. A biomarker is a molecule found in blood, fluids, or tissues that can be measured to see how the body reacts to treatments and to identify any disease condition.
Research conducted over the last decade was studied and some of the important biomarkers for diagnosing and monitoring CS and IC were found. The clinical utility of biomarkers in CS is given below.